Communiqués Teva Pharmaceutical Industries Limited

Actions

TEVA

US8816242098

Produits pharmaceutiques

Temps réel estimé Cboe BZX 20:49:19 13/08/2026			Varia. 5j.	Varia. 1 janv.
36,98 ^USD	+0,65%		+6,39%	+18,66%

16:15	Humana accepte de ne pas mentionner les liens de Teva avec Israël lors d'un procès sur le prix des médicaments aux États-Unis	RE
06/08	Teva demande à occulter ses liens avec Israël devant le jury, invoquant la guerre à Gaza	RE

Communiqués

11/08	Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy	GL
29/07	Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy	GL
10/07	Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus for Multiple Sclerosis	AQ
10/07	Teva et Polpharma Biologics annoncent la signature d’un accord de licence mondial portant sur un candidat biosimilaire à l’Ocrevus® (ocrelizumab) destiné au traitement de la sclérose en plaques	BU
09/07	Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis	BU
09/07	Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis	GL
07/07	Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results	GL
18/06	Teva Releases Q2 2026 Aide Memoire	GL
18/06	Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome	GL
18/06	Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET	GL
10/06	Teva Closes Acquisition of Emalex Biosciences, Strengthening Late-Stage Neuroscience Pipeline and Advancing Pivot to Growth Strategy	GL
08/06	Teva’s Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Highlight Long-Term Advances in Tardive Dyskinesia Treatment and Care	GL
08/06	Teva Presents New Data on AUSTEDO tablets and AUSTEDO XR extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's disease Chorea	AQ
05/06	Teva Presents New Data on AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets that Show Patient- and Caregiver-Reported Improvements in Huntington's Disease Chorea	GL
05/06	Teva Expands European biosimilars portfolio with launch of AHZANTIVE biosimilar to Eylea	AQ
04/06	Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®	GL
01/06	Teva to Present at the Goldman Sachs Global Healthcare Conference	GL
21/05	The European Medicines Agency Accepts Teva’s Marketing Authorization Application for Olanzapine Long-Acting Injectable (TEV-‘749) for the Treatment of Schizophrenia in Adults	GL
18/05	Fitch Upgrades Teva to Investment Grade Amid Pivot to Growth Execution	GL
18/05	Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact	GL
04/05	Teva to Present at the BofA Securities Health Care Conference	GL
30/04	Teva's 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets	AQ
30/04	Teva’s 2025 Healthy Future Report Highlights Environmental and Access to Medicines Progress, Including Meeting All Sustainability-Linked Bond Targets	GL
29/04	Teva Delivers Strong Q1 2026 Results Driven by Innovative Portfolio Growth and Disciplined Execution	GL
29/04	Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy	GL